Symple Surgical

Name

Symple Surgical

Legal name

Symple Surgical, Inc.

Website

https://symplesurgical.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Microwave Ablation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

akta.pro secondary industries

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

Keywords

• Microwave ablation devices
• Medical device development
• Renal denervation therapy
• Barrett's Esophagus treatment
• Resistant hypertension therapy

Headquarters

HQ city

Flagstaff

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Sales: Pre-commercial medical device company developing microwave ablation products. Planned commercialization through sale of ablation systems and disposable catheters to hospitals and outpatient facilities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Symple Surgical develops novel microwave ablation medical devices for minimally invasive therapeutic applications. Its core products are the DirectAblate GRIZZLY Microwave Ablation System for treating Barrett's Esophagus and Esophageal Adenocarcinoma via gastroenterology procedures, and the DirectAblate Renal Denervation System for treating resistant hypertension via interventional cardiology. Both products use proprietary microwave antenna technology that delivers uniform, non-contact, tissue-property-independent heating through disposable catheter-based systems.

Product overview

Symple Surgical is a privately-held medical device startup focused on developing novel therapeutic technologies using controlled Microwave Ablation. The company offers two core products: the DirectAblate GRIZZLY™ Microwave Ablation System for the treatment of Barrett's Esophagus and Esophageal Adenocarcinoma (EAC), and the DirectAblate Renal Denervation System™ for the treatment of resistant hypertension via renal sympathetic denervation. Both products leverage proprietary microwave antenna technology that can both emit and receive signals, providing automated control, feedback, and safety features. The GRIZZLY system is designed for gastroenterology procedures while the Renal Denervation system targets interventional cardiology/nephrology applications.

Differentiator

Problem solved

Functional benefit

Brands

• DirectAblate GRIZZLY Microwave Ablation System: Beside-the-scope, over-the-wire, moveable antenna, compliant urethane balloon system providing one-touch automated circumferential and focal ablations from a single disposable device up to 40mm in length for Barrett's Esophagus treatment.
• DirectAblate Renal Denervation System

Products and services

• DirectAblate GRIZZLY Microwave Ablation System A beside-the-scope, over-the-wire, moveable antenna, compliant urethane balloon catheter system designed for endoscopic treatment of Barrett's Esophagus and Esophageal Adenocarcinoma. The system delivers one-touch automated circumferential and focal ablations up to 40mm in length from a single disposable device, targeting esophagus diameters between 18-35mm. It pairs a proprietary microwave antenna with a 50W, 18GHz microwave generator to deliver precise and uniform microwave energy, intended for gastroenterologists treating the 12 million American adults with Barrett's Esophagus.
• DirectAblate Renal Denervation System A microwave ablation catheter system for renal sympathetic denervation to treat resistant hypertension, featuring a proprietary self-centering internally integrated microwave antenna, real-time surface temperature monitoring, and active arterial wall cooling for safety. It uses a 100W, 2.45GHz microwave generator with integrated control system and data acquisition to deliver a single 90-second circumferential non-contact ablation per renal artery, targeting interventional cardiologists and nephrologists treating patients with resistant hypertension.

Quantifiable outcome

• Radiofrequency ablation for treatment of Barrett's Esophagus is incompletely effective in 25% of patients studied
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Global Medical Device ManufacturercoreStrategic or Co-development Partner · 28 August 2016Collaboration and development partnership announced August 28, 2016 with a global medical device manufacturer for product development and commercialization.
• Mayo CliniccoreStrategic or Co-development PartnerCompany backed by world-class Scientific Advisory Board including clinicians and researchers from Mayo Clinic dedicated to developing therapeutic microwave technology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• NeuWave Medical (Johnson & Johnson MedTech): Acquired by Ethicon/Johnson & Johnson, NeuWave commercializes microwave ablation systems for soft tissue ablation. Comparable as a microwave ablation incumbent backed by a major med device platform with established regulatory and commercial reach.
• Boston Scientific: Major med device player with a renal denervation program (acquired Vessix) and broader interventional cardiology and endoscopy portfolios. Competes with Symple across both lead indications and represents a potential strategic acquirer.
• MicroPort Scientific: Global medical device group with interventional cardiology, electrophysiology, and endovascular franchises. Comparable as a broad interventional device incumbent pursuing similar physician call points in cardiology and GI-adjacent procedures.
• Medtronic: Global medical device leader whose Barrx system is the entrenched RF ablation standard of care for Barrett's Esophagus, and whose Symplicity Spyral catheter leads the renal denervation market. Competes directly with both Symple products but at vastly greater scale and with established clinical evidence.
• Stryker: Large diversified med device company with a meaningful ablation and interventional technologies portfolio (e.g., Interventional Spine, surgical navigation). Relevant both as a prior employer of Symple's engineering lead and as a potential strategic acquirer in the energy-based ablation space.
• Covidien (Medtronic legacy) / Emprint: Emprint (originally Covidien) is one of the most widely deployed microwave ablation platforms in interventional oncology. Comparable as a dominant incumbent in the microwave ablation modality that Symple's technology is built upon.

Emerging players

• Sonivie: Israeli emerging player developing ultrasound-based renal denervation systems for resistant hypertension. Comparable as a focused, well-funded startup in the same renal denervation market Symple targets.
• Atricure: Specializes in cardiac surgical and catheter-based ablation, including for atrial fibrillation - one of Symple's listed future expansion indications. Comparable as a focused ablation company pursuing adjacent electrophysiology targets.

Direct peers

• ReCor Medical: Focused exclusively on ultrasound-based renal denervation for resistant hypertension. Closest direct competitor in the renal denervation space Symple is targeting with the DirectAblate Renal Denervation System, competing for the same patient population and physician call point.
• AngioDynamics: Medical device company with a leading portfolio of thermal ablation systems including microwave ablation (Acculis, Solero) for soft tissue ablation. Directly comparable because it commercializes microwave ablation hardware targeting oncology and other indications, mirroring Symple's core modality. Also a former employer of Symple's Principal Engineering Leader.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/SympleSurgical
• LinkedInlinkedin.com/company/symple-surgical-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symple Surgical